Enveric Q2 10-Q: $3.0M Loss, Going Concern Warning, and $8.3M Cash
ENVB sits 23% above its 52-week low of $1.25 on light trading volume (0.3× avg).
Summary
Enveric Biosciences filed its Q2 10-Q showing a $3.0M net loss, $8.3M cash, and a going concern warning. The company raised $6.5M in financing but faces dilution and Nasdaq listing risks.
Key Events · Earnings and Guidance · ENVB
-
Q2 Net Loss of $3.0M
Net loss was $3,027,733 for Q2 2026, up from $2,519,181 in Q2 2025. Operating expenses rose 20% to $3.03M, driven by higher G&A and R&D costs.
-
Going Concern Warning Reiterated
Management states cash of $8.3M is insufficient to fund operations for 12 months, raising substantial doubt about the company's ability to continue as a going concern.
-
$6.5M Raised Through Dilutive Financing
The company raised $5.0M gross from an April private placement and $1.3M net from ATM sales, issuing 98,000 shares plus warrants for 4.4M shares. Warrants exercised added 1.95M shares.
-
Material Weaknesses in Internal Controls
Disclosure controls and procedures were not effective as of June 30, 2026, due to material weaknesses related to limited personnel, inadequate segregation of duties, and insufficient oversight.
Analysis · ENVB · Life Sciences
Enveric Biosciences reported a $3.0 million net loss for Q2 2026 with $8.3 million in cash. The company reiterated a going concern warning, stating current cash is insufficient to fund operations for 12 months. The filing also discloses material weaknesses in internal controls and a new Nasdaq listing risk. The company raised $6.5 million in financing during the quarter through private placements and ATM sales, but heavy dilution and ongoing losses keep survival uncertain.
At the time of this filing, ENVB was trading at $1.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7M. The 52-week trading range was $1.25 to $17.64. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.